AWARDS
2026 – Finalist, TechConnect World 2026 Innovation Spotlights — Critical Technology Spotlights (Advanced Materials track) for BactiBlank antibiofilm coating, Raleigh, NC.
2026 – Featured PI Highlight, Provost’s TPAC-RL Spring 2026 Faculty Newsletter, University of Notre Dame.
2024- Notre Dame Integrated Imaging Facility Award for Best Imaging Publication to Kevin Armknecht of Nallathamby lab (Nanoscale Advances, 2024, 6, 1145-1162).
2024- Nanoscale Advances, 2024, 6, 1145-1162 included in the 2024 Popular Advances collection (including articles which have been very well received by the community).
2023- 1st Prize for poster in “Antimicrobial Countermeasures for Wound Infections in Military Personnel” at the 2023 Military Health System Research Symposium in Orlando, FL
2016- $1000 for prototype submission to the InnoCentive Challenge “Minimally Invasive Skin Biopsy Technique for Gene Expression Measurement” (ID 9933669)
2016- 5th Annual Harper Research Day Poster Competition prize from the Mike and Josie Harper Cancer Research Institute
2015- Pfizer Young Investigator Poster Award for the work on “Modular Assembly of Surface Functionalized Core-Shell Nanoparticles as Novel Image Contrast Agents”
2015- $3000 InnoCentive Challenge Prize for solving “Incorporating Drugs into an Exosome” (ID 9933675)
CURRENT FEDERAL AND FOUNDATION FUNDING ($1,423,830/-)
2026 – 2028 Monoclonal Antibody-Conjugated Nanoparticles for Precision CMV Antiviral Delivery NIH R21. Maria Pilar-Perez Romero (PI), P.D. Nallathamby (Co-I). 1R21AI203022-01 $434,500.
2026 – 2029 Evaluation of Novel Antibacterial Nanoparticle Therapeutics for the Treatment of Combat-Relevant Pathogens in vitro and Pre-Clinical Animal Models, DHA MID (Invited), $295,000; 1 month Co-PI effort + 12 months graduate student; SCORE: 1.3–1.5 (Outstanding); Resubmitted October 16, 2024; Co-PI. ( Army Acquisition Contract Awarded pending ND Signature) Start Date: August 21, 2026
2025 – 2027 Multispecific Bridge Nanoparticles to Engage T Cells and Off-the-Shelf CAR-T Cells Against Antigen(+) EC Tumors to Enhance Antitumor Immune Activity, CDMRP-PRCRP IDEA award (Invited) HT94252510332, $694,330; 1.5 months effort, PI; Collaboration with IUSM-SB.
Externally Funded Projects Completed (Previous years):
2023 – 2024 AFM study to Elucidate Mechano-Electrical Differences in Cell Membranes of Cancer Cells and Normal Primary Cells using Magnetoelectric Nanoparticles, DOE-CNMS2022-B-01661, $0 (user facility access for instrument and CNMS PI time); PI: P.D. Nallathamby/L. Collins.
2022 – 2024 Off-the-Shelf CAR-T (uCAR-T) Cell Re-targeted to Multiple Cancer Types using Dual-Antibody, Bridge Nanoparticles and Controllable uCART Activation, CTSI-Think Tank/IU-B, $10,000; 0.05 months effort, PI; Milestone I met, applying for Phase II in vivo studies.
2021– 2022 Aptima /Sentinel/ND/Purdue “SMARTWATCH: Sensor-based Monitoring and Assessment via Remote Telemetry and Wearables for Augmentation of Tactical Care and Health”, NBMC-AFRL, $1,384,355.19; 4.2% FTE as senior personnel.
2020– 2021 P.D. Nallathamby, S. Zhang, F. Liu “Neutralizing the Cardiotoxicity of Anthracyclines”, American Cancer Society- Institutional Research Grant, $32,450, in vivo experiments.
2018- 2021 P.D. Nallathamby, S. Zhang, P. Helquist “Magnetic Nanocarrier-based, Precise Chemotherapeutic Delivery to Metastatic Cancer Cells In Vivo“, American Cancer Society- Institutional Research Grant, $30,000, in vivo experiments and 8% FTE.
2019 – 2020 P.D. Nallathamby, S.W. Lee, J. Hopf “Biomimetic Infection Reporting Antimicrobial Nanoparticles for Wound and Surgical Site Applications”, Clinical Translational Sciences Institute-Project Development Team, $20,000 in vitro/ in vivo supplies and 25% stipend post-doctoral salary.
PATENTS
2026 – U.S. Patent 12,576,160 B2 — “Dual antibody bridge nanoparticles for efficient targeting of cancer cells using immunotherapy (universal CAR-T cells) or other anticancer therapeutics.” Inventor: P.D. Nallathamby. Issued March 17, 2026 (Notice of Allowance Jan. 21, 2026); University of Notre Dame.
2024 – U.S. Patent 12,161,725 B2 — “Phage-Mimicking Nanoparticles.” Inventors: P.D. Nallathamby, J. Hopf. Licensed to nanoBLASTx, LLC via the Notre Dame IDEA Center, March 2026.
Recent Comments